PIPELINE

  • GCM-101

    GenCellMed's first oncolytic virus, GCM-101, has all core technologies by using EpCAM as the cell surface biomarker. GCM-101's primary targets are ovarian and prostate cancer, but it can target pancreas, breast, lung and colon cancers.

    1. * GCM-101 has efficient infection to specific cancer cells that overexpress EpCAM. Preclinical data demonstrated that administration of GCM-101 by intratumoral, intraperitoneal and intravenous reduces tumor burden in animal models.

  • 1. Double-targeting to cancer for Optimal & Efficient entry to tumor

    Engineering the Double Retargeting Technology for GCM-101

    • Sustained secretion of adapter (HVEM-scFvEpCAM) and modified recombinant gH (gH-scFvEpCAM) for priming and efficient targeting of ovarian and prostate cancer cells.
    • Self-targeting Adapter is comprised of HVEM for gD binding and scFv specific to EpCAM antigens.
    • Modified glycoprotein H (gH) is fused with scFvEpCAM to strengthen the GCM-101 to bind to the target cancer cells.
    • Single intratumoral injection of GCM-101 (2X106PFU) reduced the tumor burden by 95% in nude mice within 30 days.
    • GCM viruses replicate actively in EpCAM-positive tumors in xenograft within 48 hours after intratumoral injection (EGFP fluorescence measured).

  • 2. Enhancing Safety & Tumor Specificity to protect normal cells and tissues

    The hTERT protein expression is very low or absent in normal primary human cells from multiple tissue types but is abundant in cancer cells. This hTERT promoter technology will drive the GCM-101 replication only in cancer cells.

  • Replication of GCM-101 is similar to wild-type HSV-1 (WT HSV-1) in cancer cells (H460, lung cancer cell line) but suppressed greater than 500 folds in normal cells (HSwC, normal Schwann cell line).

  • 3. Secreting cytokines to enhance immune response for Systemic Attack on tumor

    • Multiple cytokines and chemokines are engineered into the GCM-101 genome, and the secretion of these stimulators will activate the local immune response to provide immunotherapy effects.
    • A strong systemic immune response activates cytotoxic T cells and other immune cells to attack cancer cells and enhance the eradication of cancer cells.